Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase i study

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1493-1500

  Samol, Jens ^a   Ranson, Malcolm ^b   Scott, Edwina ^c   MacPherson, Euan ^d   Carmichael, James ^d   Thomas, Anne ^c   Cassidy, James ^e  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

DNA repair; Maximum tolerated dose; Olaparib; PARP inhibitors; Targeted agents; Topotecan

Indexed keywords

OLAPARIB; STEROID; TOPOTECAN;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD TOXICITY; CARCINOID; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; LETHARGY; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDIASTINAL CARCINOID; MEDIASTINUM CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPENIC SEPSIS; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THYMUS CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UTERUS SARCOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; TOMOGRAPHY, X-RAY COMPUTED; TOPOTECAN; TREATMENT OUTCOME;

EID: 84866564290     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9682-9     Document Type: Article

References (24)

1. Hoeijmakers JH. (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366-374
2. Virag L, Szabo C. (2002) The therapeutic potential of poly(ADPribose) polymerase inhibitors. Pharmacol Rev 54:375-429
3. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM. (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2 H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51:6581-6591
4. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079-17084
5. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J. (2008) Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14:3916-3925
6. Zander SA, Kersbergen A, van de Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S. (2010) Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 70:1700-1710
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134
8. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JHM, de Bono JS, Kaye SB. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519
9. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-251
10. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. (2010) Oral poly. (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244
11. Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. (1999) Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1-12
12. ten Bokkel HW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF. (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R. (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658
15. Zhao W, Duan W, Leon ME, Chen AP, Sofletea G, Thurmond B, Ramaswamy B, O'Malley D, Bekaii-Saab TS, Villalona-Calero MA. (2010) Targeting fanconi anemia. (FA)' repair pathway deficiency for treatment with PARP inhibitors. J Clin Oncol 28. (23s):abst TPS168
16. Knights C, Chresta C, Riches L, Mangena R, Avis T, O'Shaughnessy A, Unwin L, Dunham V, Jones L, Cranston A, Carmichael J, Martin N, O'Connor M, Lau A. (2009) Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient. (HRD) MRE11 mutant microsatellite instable. (MSI) colorectal cancer. Mol Cancer Ther 8(12 Suppl):A114
17. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, MacPherson E, Oza AM. (2010) Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple negative breast cancer. J Clin Oncol 28(15S):abst 3002
18. Borst P, Jonkers J, Rottenberg S. (2007) What makes tumors multidrug resistant? Cell Cycle 6:2782-2787
19. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, AshworthA. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115
20. Haslam IS, Jones K, Coleman T, Simmons NL. (2008) Induction of P-glycoprotein expression and function in human intestinal epithelial cells. (T84). Biochem Pharmacol 76:850-861
21. Schuetz E, Lan L, Yasuda K, Kim R, Kocarek TA, Schuetz J, Strom S. (2002) Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62:439-445
22. Giaccone G, Rajan A, Kelly RJ, Gutierrez M, Kummar S, Yancey M, Ji JJ, Zhang Y, Parchment RE, Doroshow JH. (2010) A Phase I combination study of olaparib. (AZD2281; KU-0059436) and cisplatin. (C) plus gemcitabine. (G) in adults with solid tumors. J Clin Oncol 28(15S):abst 3027
23. Dent RA, Lindeman G, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Kemlsey K, Carmichael J. (2010) Safety and efficacy of the oral PARP inhibitor olaparib. (AZD2281) in combination with paclitaxel for the 1st or 2nd line treatment of patients with metastatic triple negative breast cancer: results from the safety cohort of a Phase 1/2 multicentre trial. J Clin Oncol 28(15S):abst 1018
24. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214